Luxembourg, 16/12/2019

Public Environmental and Social Data Sheet

Overview

Project Name: AM-PHARMA
Project Number: 2019-0318
Country: The Netherlands
Project Description: The Promoter is a Dutch biopharmaceutical company developing a proprietary enzyme that has the potential to transform the treatment prospects for patients with sepsis-induced conditions, such as Sepsis-Associated Acute Kidney Injuries (SA-AKI).

EIA required: no
Project included in Carbon Footprint Exercise¹: no
(details for projects included are provided in section: “EIB Carbon Footprint Exercise”)

Environmental and Social Assessment

Environmental Assessment

The project concerns investments in research and development activities, carried out by the Promoter and its partners in existing facilities without changing their already authorised scope. An Environmental Impact Assessment (EIA) is therefore not required under EIA Directive 2014/52/EU amending Directive 2011/92/EU.

The promoter maintains adequate internal procedures and management practices that are in line with best industry standards and are subjected to regular external audits.

Other Environmental and Social Aspects

If successful, the project is expected to lead to important social benefits, considering the increased incidence of sepsis and comorbidities, coupled with high-unmet medical needs, which could potentially relieve a significant burden on health services.

Through the RDI activities and investments, the Promoter is also expected to sustain its current level of highly skilled personnel, while contributing to European scientific innovation, hence fostering and nurturing the vital research community.

¹ Only projects that meet the scope of the Pilot Exercise, as defined in the EIB draft Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tons CO2e/year absolute (gross) or 20,000 tons CO2e/year relative (net) – both increases and savings.
Conclusions and Recommendations

Considering the above, the project is deemed acceptable for the Bank's financing under environmental and social terms.

PJ/SQM/ECSO 29.10.2019